background

Press Releases

Royalty Pharma Announces Acquisition of Royalty Rights on Global Sales of Sacituzumab Govitecan (IMMU-132) for $175 Million

Royalty Pharma and Immunomedics, Inc., (NASDAQ: IMMU) today announced that Immunomedics has agreed to sell tiered, sales-based royalty rights on global net sales of sacituzumab govitecan to Royalty Pharma for $175 million.

Read MoreDownload

Royalty Pharma Announces $2.85 Billion Acquisition of Royalty Rights in Multiple Sclerosis Drug Tysabri® (natalizumab) from Perrigo Company plc

Royalty Pharma buys royalty on worldwide sales of Tysabri® (natalizumab) for $2.2 billion plus potential milestone payments of $250 million in 2018 and $400 million in 2020 to be paid if Tysabri sales exceed certain levels.

Read MoreDownload

Royalty Pharma Announces $100 million Acquisition of Royalty Rights in cardiovascular drug Omecamtiv Mecarbil from Cytokinetics

Royalty Pharma buys royalty on worldwide sales of Omecamtiv Mecarbil. Cytokinetics agrees to exercise option to co-fund Phase 3 development program under collaboration with Amgen for increased royalty and co-promotion rights in North America.

Read MoreDownload

Royalty Pharma Announces $1.14 Billion Acquisition of Royalty Rights in Cancer Drug Xtandi from the University of California, Los Angeles (UCLA)

Royalty Pharma Announces $1.14 billion Acquisition of Royalty Rights in cancer drug Xtandi from the University of California, Los Angeles (UCLA).

Read MoreDownload

Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics

Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics’ (“CFFT”), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion.

Read MoreDownload

Avillion Announces Royalty Pharma Investment

Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development through marketing approval, announced that Royalty Pharma has become an investor, joining Abingworth LLP and Clarus Ventures.

Read MoreDownload

Forest Laboratories and Royalty Pharma Announce Acquisition of Furiex Pharmaceuticals

Royalty Pharma announced today that it is partnering with Forest Laboratories (NYSE: FRX) to acquire Furiex Pharmaceuticals (NASDAQ: FURX). Forest is acquiring Furiex for $1.4 billion and Royalty Pharma is acquiring two royalties from Furiex (primarily a royalty on Takeda’s Nesina®), for $415 million in cash.

Read MoreDownload

Royalty Pharma Announces Additional $510 Million Acquisition of Interest in Tecfidera and Fumaderm

Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash.

Read MoreDownload

FDA approves Imbruvica (ibrutinib) for mantle cell lymphoma (MCL)

The U. S. Food and Drug Administration granted accelerated approval to Imbruvica (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Read MoreDownload

Royalty Pharma Acquires Ibrutinib Royalty Rights for $485 Million In Cash

Royalty Pharma announced today that it has acquired certain rights to receive royalties on future sales of drug candidate ibrutinib from Quest Diagnostics for $485 million in cash.

Read MoreDownload

Royalty Pharma Announces Withdrawal of Judicial Review and Lapse of Offer

Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel’s decision requiring it to lapse its offer for Elan Corporation, plc (NYSE: ELN) if, among other things, Elan shareholders approved the Share Repurchase Program.

Read MoreDownload

Royalty Pharma Raises $600 Million of Debt

Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully issued $600 million of incremental Term Loan B debt through RPI Finance Trust (“RPIFT”), bringing total debt outstanding at RPIFT to approximately $3.4 billion. Proceeds will be used to fund future acquisitions.

Read MoreDownload

Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm

Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Read MoreDownload

Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement

Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis’ lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.

Read More

Royalty Pharma Acquires Cimzia® and Mircera® Royalties for $124 Million

Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million.

Read MoreDownload

Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million

Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million.

Read MoreDownload

Royalty Pharma Raises $3.6 Billion to Refinance $2.75 Billion of Outstanding Debt and to Fund an $850 Million Cash Distribution to Shareholders

Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.

Read MoreDownload

Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement

Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million.

Read MoreDownload

Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million

Astellas Pharma Inc. announced today that Prosidion’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of $609 million. The transaction is expected to close in July 2011.

Read MoreDownload

Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million

Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.

Read More

Cypress Bioscience Agrees to be Acquired by Ramius LLC and Royalty Pharma for $6.50 per Share in Cash

Cypress Bioscience, Inc. (Nasdaq: CYPB) (“Cypress”), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, announced today that it has entered into a definitive merger agreement with Ramius V&O Acquisition LLC, an affiliate of Ramius LLC (collectively, “Ramius”) and affiliates of Royalty Pharma (“Royalty Pharma”), providing for the acquisition of Cypress by Ramius and Royalty Pharma.

Read More

Royalty Pharma Acquires Royalty Interest in RotaTeq® from The Children’s Hospital Foundation for $182 Million

The Children’s Hospital Foundation, the parent company of The Children’s Hospital of Philadelphia® (CHOP) and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq® from and after October 1, 2007, to Royalty Pharma for $182 million in cash.

Read More

Royalty Pharma Acquires a Portion of Northwestern University’s Royalty Interest in Lyrica® for $700 Million

Royalty Pharma and Northwestern University announced today that Northwestern has sold a portion of its worldwide royalty interest in Lyrica® to Royalty Pharma for $700 million in cash.

Read More

Royalty Pharma Acquires a Portion of New York University’s Royalty Interest in Remicade® for $650 Million

Royalty Pharma and New York University (NYU) announced today that NYU has sold a portion of NYU’s worldwide royalty interest in Remicade® to Royalty Pharma.

Read More

Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA® from AstraZeneca and CAT

Royalty Pharma announced today that it has completed the purchase of the rights to a pre-existing royalty interest in HUMIRA® currently held by AstraZeneca plc’s subsidiary, Cambridge Antibody Technology Limited (CAT).

Read More

Emory Drug Deal Turns Heads

Jumbo $525 Million Royalty Rights Payment Captures Wall Street’s Attention. Wall Street is rubbing its hands in anticipation of more to come after Emory University’s groundbreaking deal to sell the royalty rights for an HIV drug developed by school researchers. Gilead Sciences and Royalty Pharma paid a whopping $525 million for the rights, the largest lump-sum royalty payment to a US university to date.

Read More

Royalty Pharma Acquires Memorial Sloan-Kettering Cancer Center’s International Royalty Interest in Neupogen® and Neulasta® for $142 Million

Royalty Pharma and Memorial Sloan-Kettering Cancer Center ("MSKCC") announced today that they have completed the sale of a portion of MSKCC’s royalty interest in Neupogen® and Neulasta® worldwide for all countries except the United States, China, Japan, South Korea, North Korea and Taiwan.

Read More

Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine

Gilead Sciences, Inc. (Nasdaq: GILD) and Royalty Pharma today announced that the companies have entered into an agreement with Emory University providing for the purchase of the royalty interest owed to Emory for emtricitabine, also known as Emtriva®. Under the terms of the agreement, Gilead and Royalty Pharma will make a one-time cash payment of $525 million to Emory in exchange for elimination of the emtricitabine royalties due to Emory on worldwide net sales of the product.

Read More

Ligand, Royalty Pharma Amend SERM Royalty Agreement

Royalty Pharma Accelerates and Increases Royalty Purchase to $32.5 Million as Substitute for Final Two Options. Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing final stages of development, the companies announced today.

Read More

Royalty Pharma Acquires a Portion of Memorial Sloan-Kettering Cancer Center’s US Royalty Interest in Neupogen/Neulasta

Royalty Pharma acquired a portion of Memorial Sloan-Kettering Cancer Center’s (MSKCC) US royalty interest in Neupogen/Neulasta, the entities announced today. Under the agreement, MSKCC received $263 million in cash up-front plus certain additional payments should Neupogen/Neulasta yearly sales exceed certain agreed sales hurdles. In addition, as part of the agreement, MSKCC has made a $7 million investment in Royalty Pharma.

Read More

Ligand, Royalty Pharma Amend SERM Royalty Agreement

Royalty Pharma Exercises a $12.5 Million Option on October 1. Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing completion of Phase III development, the companies announced today.

Read MoreDownload

Standard & Poors - Royalty Pharma Finance Trust

Royalty Pharma Finance Trust Rating: AAA

Read More

Moody's Rates Royalty Pharma Pharmaceutical Royalty Securitization Aaa

Approximately $225 Million of Asset-Backed Securities Rated Aaa. Moody's Investors Service has assigned a rating of Aaa to the $225,000,000 asset-backed note issued by Royalty Pharma Finance Trust (RPFT). The notes are backed initially by a pool of royalty interests and contingent pay rights in thirteen biopharmaceutical products. This is the first time Moody's has assigned a term rating to a transaction backed by biopharmaceutical royalty interests.

Read MoreDownload

Ligand, Royalty Pharma Expand SERM Royalty Agreement, Form New Royalty Partnership for Targretin Capsules

Ligand to use increased proceeds of up to $15.4 million through 2003 to accelerate development of Targretin Capsules in NSCLC monotherapy and Targretin Gel in hand dermatitis

Read MoreDownload

Ligand to Receive $3.5 Million as Royalty Pharma Exercises Another Option to Purchase Additional Rights to Future SERM Royalty Streams

Ligand Pharmaceuticals (Nasdaq: LGND) expects to receive $3.5 million this quarter from Royalty Pharma AG, which has formally notified Ligand that it intends to exercise its September 30 option to purchase an additional 0.125% of potential future sales of three selective estrogen receptor modulator (SERM) products now in Phase III development. Payment is subject to the usual conditions of the agreement between the parties.

Read MoreDownload

Ligand to Receive $3 Million as Royalty Pharma Exercises First Option to Purchase Additional Rights to Future SERM Royalty Streams

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) expects to receive $3 million this quarter from Royalty Pharma AG, which has formally notified Ligand that it intends to exercise its first option to purchase an additional 0.125% of potential future sales of three selective estrogen receptor modulator (SERM) products now in Phase III development. Payment is subject to the usual conditions of the agreement between the parties.

Read MoreDownload

Ligand, Royalty Pharma Conclude Agreement for Rights/Options Tied to Future SERM Royalty Streams

Payments of up to $56 Million Enable Additional Investments in R&D 2002-2004. Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today an agreement with Royalty Pharma AG, which has purchased rights to a share of future payments from Ligand’s collaborative partners’ sales of three selective estrogen receptor modulator (SERM) products now in Phase III development.

Read More

EntreMed Sells Thalidomide Royalty Stream for $24.3 Million

EntreMed, Inc. (Nasdaq: ENMD) announced today that it sold its rights to future royalties from the sales of thalidomide (THALOMID(R)). EntreMed received $24.3 million from Royalty Pharma AG, a Swiss stock corporation, and may receive an additional $3 million if certain sales milestones are achieved. Furthermore, if total and annual sales exceed established thresholds, EntreMed would receive from Royalty Pharma AG a share of certain royalty payments.

Read MoreDownload

Xoma Receives $17 Million for Anti-CD20 Antibody Patents and Related Rights and $10 Million from Genentech for 1998 hu1124 Program

XOMA Corporation (Nasdaq: XOMA) announced today that it has received $27 million in cash from two separate sources late in 1997, resulting in an year-end cash position of approximately $55 million.

Read MoreDownload